| 4.39 0.11 (2.57%) | 11-29 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.2 |
1-year : | 6.07 |
| Resists | First : | 4.45 |
Second : | 5.2 |
| Pivot price | 3.66 |
|||
| Supports | First : | 3.61 |
Second : | 3.08 |
| MAs | MA(5) : | 4.11 |
MA(20) : | 3.6 |
| MA(100) : | 2.7 |
MA(250) : | 2.27 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 90.8 |
D(3) : | 85.2 |
| RSI | RSI(14): 73 |
|||
| 52-week | High : | 4.45 | Low : | 1.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CKPT ] has closed below upper band by 0.1%. Bollinger Bands are 121.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.32 - 4.33 | 4.33 - 4.34 |
| Low: | 4.01 - 4.03 | 4.03 - 4.04 |
| Close: | 4.25 - 4.28 | 4.28 - 4.3 |
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Thu, 14 Nov 2024
Checkpoint Therapeutics: Preparing For Cosibelimab’s Upcoming PDUFA Date (NASDAQ:CKPT) - Seeking Alpha
Tue, 12 Nov 2024
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Tue, 12 Nov 2024
Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | CKPT Stock News - StockTitan
Thu, 24 Oct 2024
Checkpoint Therapeutics stock hits 52-week high at $3.62 - Investing.com
Tue, 27 Aug 2024
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 3.479e+007 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 4,380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -16 % |
| Return on Assets (ttm) | 275.6 % |
| Return on Equity (ttm) | -316.8 % |
| Qtrly Rev. Growth | 78000 % |
| Gross Profit (p.s.) | 26.04 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.59 |
| Dividend | 0 |
| Forward Dividend | 5.56e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|